Vectans Pharma - Transmucosal technology, targeted efficacy, improved compliance

ABOUT VECTANS PHARMA

Vectans Pharma is an international pharmaceutical company bringing a new therapeutic approach with its Lauriad^® technology born of French R&D.

This innovative technology enables targeted and prolonged diffusion of APIs, thus optimizing effectiveness and compliance for the benefit of patients.

Vectans Pharma's portfolio currently comprises two products, Sitavig^® and Loramyc^®, both market-approved by American (FDA), European (EMA) and Japanese (PMDA) health authorities.

Through international licensing agreements, Loramyc^®; is commercialized in the United States, Japan, Italy and France, and Sitavig^®; in the United States and France.

NEWS

LORAMYC® 50 mg: BfArM grants a 3-year exemption from the sunset clause

The BfArM granted a 3-year exemption of the sunset clause for LORAMYC® 50 mg.

Exclusive licensing agreement with m8 Pharmaceuticals

m8 Pharmaceuticals and Vectans Pharma signed an exclusive licensing agreement of Loramyc® (miconazole Lauriad®) for Mexico and Brazil.

ABOUT VECTANS PHARMA

Vectans Pharma is an international pharmaceutical company with an innovative drug delivery technology that brings clear benefits to patients. Through international licensing agreements, Vectans Pharma products are commercialized in the United States, Latin America, Asia and Europe.

SITEMAP

LAURIAD^® TECHNOLOGY

CONTACT

+33(0)1.41.21.90.16
[email protected]

230 Bureaux de la colline
92213 SAINT CLOUD
France

Copyright © VECTANS PHARMA

Legal notices and privacy policy